Vaxart (NASDAQ:VXRT) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Vaxart (NASDAQ:VXRT) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05, Zacks reports. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.

Vaxart Stock Down 2.8 %

Shares of NASDAQ:VXRT opened at $0.57 on Friday. Vaxart has a fifty-two week low of $0.45 and a fifty-two week high of $1.41. The company has a market cap of $129.14 million, a PE ratio of -1.38 and a beta of 1.69. The company’s 50-day moving average price is $0.65 and its 200 day moving average price is $0.71.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.